J.P. Morgan Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Cuts Target Price to $48
Rocket Pharmaceuticals Price Target Lowered to $48 From $49 at JPMorgan
Wedbush Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $32
Buy Recommendation for Rocket Pharmaceuticals: Promising Potential of RP-L301 in Severe PKD Cases
Top 3 Health Care Stocks That Could Blast Off This Month
BofA Securities Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $37
Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Major firms rating丨Wedbush: Initiated coverage on Rocket Pharmaceuticals with an "Outperform" rating.
Wedbush initiates coverage of Rocket Pharmaceuticals with an "Outperform" rating and a Target Price of $32. Ongoing pipeline development and internal capacity are expected to support the company's long-term growth potential. (Gelonghui)
Sector Update: Health Care Stocks Softer Late Afternoon
Rocket Pharmaceuticals' Continued Pipeline Development to Support Long-Term Growth Potential, Wedbush Says
Wedbush Starts Rocket Pharmaceuticals With Outperform Into 'Inflection Year'
Wedbush Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Cuts Target Price to $32
Promising Pipeline and Strategic Developments Propel Rocket Pharmaceuticals to 'Buy' Rating
Express News | Rocket Pharmaceuticals Inc : Wedbush Initiates Coverage With Outperform Rating; Price Target $32
Rocket Pharmaceuticals, Inc. (RCKT): Is This Gene Therapy Stock a Good Buy Right Now?
Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy'
Rocket Pharmaceuticals Price Target Announced at $29.00/Share by Jefferies
Rocket Pharmaceuticals Analyst Ratings
Jefferies Initiates Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Announces Target Price $29
Leerink Partners Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Cuts Target Price to $40
No Data